Roche Eyes Adjuvant HCC Setting After Phase III Tecentriq Combination Success
But Market Opportunity Limited
Executive Summary
The firm’s Tecentriq has bounced back from recent setbacks with a pivotal success in the adjuvant liver cancer setting.
You may also be interested in...
Questions Overshadow Roche’s Bid To Make Tecentriq First Adjuvant Liver Cancer Treatment
Despite recording the first success for an adjuvant drug therapy in hepatocellular carcinoma, Roche is likely to need longer-term safety and efficacy data before attempting a filing.
Roche Withdraws Tecentriq’s Frontline Bladder Cancer Indication, Ceding Market To Keytruda
The move marks the second time since last year that Roche has withdrawn a urothelial carcinoma indication after its confirmatory trial failed to show an overall survival benefit.
Vabysmo Is Bright Spot For Roche In Bumpy Q3
Roche's pharma revenues declined in the third quarter, but the Swiss major is hoping that Tecentriq in adjuvant settings can boost future revenues – and that, just maybe, it will have a win from its Alzheimer’s candidate too.